MA51075A - Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine - Google Patents

Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Info

Publication number
MA51075A
MA51075A MA051075A MA51075A MA51075A MA 51075 A MA51075 A MA 51075A MA 051075 A MA051075 A MA 051075A MA 51075 A MA51075 A MA 51075A MA 51075 A MA51075 A MA 51075A
Authority
MA
Morocco
Prior art keywords
compositions
methods
treating disorders
follistatin polypeptides
follistatin
Prior art date
Application number
MA051075A
Other languages
English (en)
Inventor
Asya Grinberg
Ravindra Kumar
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA51075A publication Critical patent/MA51075A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051075A 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine MA51075A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04

Publications (1)

Publication Number Publication Date
MA51075A true MA51075A (fr) 2020-10-14

Family

ID=54767384

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051075A MA51075A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
MA051074A MA51074A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051074A MA51074A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Country Status (12)

Country Link
US (2) US10023621B2 (fr)
EP (2) EP3721892B1 (fr)
JP (3) JP6568110B2 (fr)
KR (4) KR102132144B1 (fr)
CN (2) CN106795224B (fr)
AU (2) AU2015269333B2 (fr)
BR (1) BR112016028520A2 (fr)
CA (1) CA2950754C (fr)
EA (2) EA202090632A1 (fr)
MA (2) MA51075A (fr)
MX (2) MX382908B (fr)
WO (1) WO2015187977A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00380B (fr) 2005-11-23 2011-10-10 Acceleron Pharma Inc Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
KR101871510B1 (ko) 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
WO2014116981A1 (fr) 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatine dans le traitement de la dystrophie musculaire de duchenne
CN106795224B (zh) * 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
WO2016154601A1 (fr) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Protéines de fusion associées à la follistatine et leurs utilisations
CN109153708A (zh) * 2016-03-04 2019-01-04 夏尔人类遗传性治疗公司 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良症中的应用
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (fr) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute Procédé thérapeutique pour augmenter la masse musculaire chez un sujet
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
JP2021515576A (ja) * 2018-03-16 2021-06-24 イミュソフト コーポレーション フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
EP3769779B1 (fr) * 2018-03-21 2023-12-27 Soulyoung Biotech Co., Ltd Composition visant à favoriser la croissance musculaire locale ou à ralentir ou prévenir l'atrophie musculaire locale et son utilisation
WO2019191204A1 (fr) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Polypeptides de follistatine pour le traitement de la contracture musculaire
AU2019269702A1 (en) * 2018-05-17 2020-12-24 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
WO2020046466A1 (fr) * 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Méthodes pour atténuer, inhiber ou inverser une atrophie musculaire par inaction chez le mammifère
WO2021222875A1 (fr) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Procédés d'utilisation d'inhibiteurs d'alk2
WO2022098812A1 (fr) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Méthodes de traitement d'une surcharge en fer
KR20230165900A (ko) * 2021-01-26 2023-12-05 이뮤니스, 아이엔씨. 분자 초구조 및 이의 사용 방법
CN119654337A (zh) 2022-06-15 2025-03-18 Ucb生物制药有限责任公司 用于预防、治疗或改善肾脏疾病的融合蛋白
WO2023242251A1 (fr) 2022-06-15 2023-12-21 UCB Biopharma SRL Protéines de fusion follistatines-fc
WO2024121351A1 (fr) * 2022-12-07 2024-06-13 Lodberg Andreas Composés de liaison à une matrice extracellulaire pour le chargement localisé d'agents thérapeutiques ou diagnostiques
TW202530250A (zh) * 2024-01-25 2025-08-01 大陸商四川至善唯新生物科技有限公司 編碼卵泡抑素的核酸及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (fr) 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
EP1340769B1 (fr) * 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. Chimères de CD4-gamma2 et de CD4-IgG2
DE69310525T2 (de) 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
EP1147413B1 (fr) 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibiteurs de facteurs de differenciation de la croissance et leurs utilisations
CA2365449A1 (fr) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de croissance de la tumeur androgeno-independante
WO2001009368A1 (fr) 1999-07-30 2001-02-08 The General Hospital Corporation Antagonistes de la follistatine
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
PL375045A1 (en) 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
ATE474593T1 (de) 2003-03-21 2010-08-15 Celldex Therapeutics Ltd Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
WO2004108157A2 (fr) 2003-06-02 2004-12-16 Wyeth Methodes de traitement et de prevention des troubles neuromusculaires
WO2005025601A1 (fr) 2003-09-15 2005-03-24 Monash University Isoformes de follistatine et leurs utilisations
WO2005033134A2 (fr) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Therapeutique et utilisations d'une proteine secretee
CA2541237C (fr) 2003-10-06 2015-12-01 Monash University Modulation de l'activine pour modifier les reactions inflammatoires
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
ES2561048T3 (es) * 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1915397B1 (fr) 2005-08-19 2015-01-14 Wyeth LLC Anticorps antagonistes contre gdf-8 et utilisations pour le traitement de als et d'autres troubles associes a gdf-8
CA2632544C (fr) * 2005-12-06 2014-09-23 Amgen Inc. Utilisations d'antagonistes de la myostatine
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
ES2569365T3 (es) 2006-11-29 2016-05-10 Nationwide Children's Hospital Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
KR101871510B1 (ko) 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
CN107252486B (zh) * 2008-06-26 2021-10-22 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
ES2613523T3 (es) * 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
TW201215405A (en) 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2834259A4 (fr) * 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
WO2013170315A1 (fr) 2012-05-17 2013-11-21 Paranta Biosciences Limited Procédé de traitement et agents utiles pour celui-ci
US9943574B2 (en) * 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
WO2014116981A1 (fr) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatine dans le traitement de la dystrophie musculaire de duchenne
WO2014187807A1 (fr) * 2013-05-21 2014-11-27 Arcarios B.V. Dérivés de follistatine
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2016154601A1 (fr) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Protéines de fusion associées à la follistatine et leurs utilisations
WO2018209242A1 (fr) 2017-05-12 2018-11-15 Shire Human Genetic Therapies, Inc. Protéines de fusion follistatine-fc recombinantes et leur utilisation dans le traitement de la dystrophie musculaire de duchenne

Also Published As

Publication number Publication date
KR20200084064A (ko) 2020-07-09
EP3152237A4 (fr) 2017-11-01
EP3152237B1 (fr) 2020-04-01
EA202090632A1 (ru) 2020-07-31
EP3721892A1 (fr) 2020-10-14
KR20210119546A (ko) 2021-10-05
CA2950754A1 (fr) 2015-12-10
CA2950754C (fr) 2021-10-26
MX2021006017A (es) 2021-07-06
US10954279B2 (en) 2021-03-23
BR112016028520A2 (pt) 2017-10-24
KR102077286B1 (ko) 2020-02-13
CN106795224B (zh) 2021-05-18
KR102132144B1 (ko) 2020-07-09
US20160185836A1 (en) 2016-06-30
EP3152237A1 (fr) 2017-04-12
JP6856716B2 (ja) 2021-04-07
AU2020210315A1 (en) 2020-08-27
MA51074A (fr) 2020-10-14
MX382908B (es) 2025-03-13
JP2021095416A (ja) 2021-06-24
CN106795224A (zh) 2017-05-31
EP3721892B1 (fr) 2024-05-22
JP2019203017A (ja) 2019-11-28
WO2015187977A1 (fr) 2015-12-10
EA035455B1 (ru) 2020-06-18
AU2015269333B2 (en) 2020-05-07
JP6568110B2 (ja) 2019-08-28
JP2017518303A (ja) 2017-07-06
AU2015269333A1 (en) 2016-12-15
KR20170005891A (ko) 2017-01-16
US10023621B2 (en) 2018-07-17
EA201692529A1 (ru) 2017-05-31
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
MX2016015868A (es) 2017-04-05
CN113583104A (zh) 2021-11-02
KR102305109B1 (ko) 2021-09-27

Similar Documents

Publication Publication Date Title
MA51074A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
EP3324960A4 (fr) Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
EP3319976A4 (fr) Compositions et procédés pour traiter des maladies pulmonaires et des lésions pulmonaires
SI3206493T1 (sl) Sestavki in metode za zdravljenje CNS motenj
PT3224269T (pt) Composições e métodos para tratamento de distúrbios do snc
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
SMT202100113T1 (it) Composizioni e metodi per trattare disturbi del snc
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
MA44886A (fr) Compositions et méthode pour traiter des troubles acide-base
EP3331542A4 (fr) Compositions et procédés pour traiter des cancers associés à l'activation d'etbr
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
EP3703706A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
EP3661492A4 (fr) Procédés et compositions pour traiter des troubles neurologiques
EP3506927A4 (fr) Compositions de reeline pour le traitement des troubles neurologiques
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3344337A4 (fr) Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
EP3294339A4 (fr) Méthodes et compositions pour le traitement de l'arthrite